董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Karah Parschauer | 女 | Independent Director | 47 | 27.20万美元 | 13.68 | 2025-09-08 |
| Vikram Malik | 男 | Chairman of the Board | 62 | 32.10万美元 | 35.51 | 2025-09-08 |
| Albert G. White III | 男 | Independent Director | 55 | 26.40万美元 | 5.00 | 2025-09-08 |
| David Gill | 男 | Independent Director | 70 | 29.30万美元 | 15.70 | 2025-09-08 |
| David Moatazedi | 男 | Director, President and Chief Executive Officer | 47 | 641.22万美元 | 185.08 | 2025-09-08 |
| Brady Stewart | 男 | Independent Director | 49 | 26.50万美元 | 12.09 | 2025-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rui Avelar | 男 | Head of Research and Development and Chief Medical Officer | 63 | 169.91万美元 | 74.14 | 2025-09-08 |
| Tatjana Mitchell | 女 | Chief Financial Officer | 47 | 316.33万美元 | 未持股 | 2025-09-08 |
| David Moatazedi | 男 | Director, President and Chief Executive Officer | 47 | 641.22万美元 | 185.08 | 2025-09-08 |
董事简历
中英对照 | 中文 | 英文- Karah Parschauer
-
Karah Parschauer自2016年6月起担任Ultragenyx Pharmacetuical Inc.（Ultragenyx”；）的总法律顾问兼执行Vice President，该公司是我们的重要股东。Parschauer女士以这种身份领导Ultragenyx&8217；的法律，合规和政府事务职能。自2019年7月起，Parschauer女士一直担任Evolus，Inc.（EOL）的董事。在加入Ultragenyx之前，Parschauer女士最近于2005年6月至2016年6月担任制药公司Allergan plc的副总法律顾问Vice President。在Allergan之前，Parschauer女士是Latham&Watkins LLP的律师。Parschauer女士拥有迈阿密大学（Miami University）的学士学位和哈佛大学法学院（Harvard Law School）的法学博士学位。
Karah Parschauer,has held various roles at Ultragenyx Pharmacetuicals, Inc., a biopharmaceutical company, including as Chief Legal Officer & Corporate Affairs, Executive Vice President since February 2023, as Chief Legal Officer and Executive Vice President since December 2021 and as General Counsel and Executive Vice President since June 2016. Prior to Ultragenyx, Mrs. Parschauer served in various executive capacities, and most recently as Vice President, Associate General Counsel, at Allergan, a pharmaceutical company, from June 2005 until June 2016. Prior to Allergan, Mrs. Parschauer was an attorney at Latham & Watkins LLP, where she practiced in the areas of mergers and acquisitions, securities offerings, and corporate governance. Mrs. Parschauer holds a B.A. in Biology from Miami University and a J.D. from Harvard Law School. - Karah Parschauer自2016年6月起担任Ultragenyx Pharmacetuical Inc.（Ultragenyx”；）的总法律顾问兼执行Vice President，该公司是我们的重要股东。Parschauer女士以这种身份领导Ultragenyx&8217；的法律，合规和政府事务职能。自2019年7月起，Parschauer女士一直担任Evolus，Inc.（EOL）的董事。在加入Ultragenyx之前，Parschauer女士最近于2005年6月至2016年6月担任制药公司Allergan plc的副总法律顾问Vice President。在Allergan之前，Parschauer女士是Latham&Watkins LLP的律师。Parschauer女士拥有迈阿密大学（Miami University）的学士学位和哈佛大学法学院（Harvard Law School）的法学博士学位。
- Karah Parschauer,has held various roles at Ultragenyx Pharmacetuicals, Inc., a biopharmaceutical company, including as Chief Legal Officer & Corporate Affairs, Executive Vice President since February 2023, as Chief Legal Officer and Executive Vice President since December 2021 and as General Counsel and Executive Vice President since June 2016. Prior to Ultragenyx, Mrs. Parschauer served in various executive capacities, and most recently as Vice President, Associate General Counsel, at Allergan, a pharmaceutical company, from June 2005 until June 2016. Prior to Allergan, Mrs. Parschauer was an attorney at Latham & Watkins LLP, where she practiced in the areas of mergers and acquisitions, securities offerings, and corporate governance. Mrs. Parschauer holds a B.A. in Biology from Miami University and a J.D. from Harvard Law School.
- Vikram Malik
-
Vikram Malik，自2018年1月起担任我们的董事会成员和主席。Malik先生自2014年4月起担任Alphaeon’；的董事会成员。Malik先生从2013年5月开始担任SCH的管理合伙人。Malik从2011年8月到2013年5月担任Deutsche Bank Securities，Inc.投资银行副董事长。Malik从2010年11月到2011年8月担任Merrill Lynch，Pierce，Fenner&Smith Incorporated梦百合Corporate and Investment Banking Group总经理。从2000年6月到2010年11月，Malik先生担任Banc of America Securities，LLC的常务董事。Malik先生在德里大学（Delhi University）获得经济学学士学位，并在波士顿大学管理研究生院（Boston University Graduate School of Management）获得工商管理硕士学位。
Vikram Malik,serves as Chairman of the board of directors of Alphaeon Credit Inc., a consumer credit provider to the aesthetics industry and as a member of the board of directors of Crown Sterling Limited, LLC, a social media technology company and Ceyeber Inc., an ophthalmic medical device company. From December 2020 to July 2023, Mr. Malik served as President and a director of Priveterra Acquisition Corp. a blank-check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. From April 2014 to July 2023, Mr. Malik served on the board of directors of Aeon Biopharma. From May 2013 to June 2022, Mr. Malik served as the Managing Partner of Strathspey Crown Holdings Group, LLC, a growth equity firm. From August 2011 to May 2013, Mr. Malik served as Vice Chairman, Investment Banking for Deutsche Bank Securities, Inc. From November 2010 to August 2011, Mr. Malik served as a Managing Director in the Healthcare Corporate and Investment Banking Group of Merrill Lynch, Pierce, Fenner & Smith Incorporated. From June 2000 to November 2010, Mr. Malik served as the Managing Director of Banc of America Securities, LLC. Mr. Malik received a B.A. in Economics from Delhi University and an M.B.A. from Boston University Graduate School of Management. - Vikram Malik，自2018年1月起担任我们的董事会成员和主席。Malik先生自2014年4月起担任Alphaeon’；的董事会成员。Malik先生从2013年5月开始担任SCH的管理合伙人。Malik从2011年8月到2013年5月担任Deutsche Bank Securities，Inc.投资银行副董事长。Malik从2010年11月到2011年8月担任Merrill Lynch，Pierce，Fenner&Smith Incorporated梦百合Corporate and Investment Banking Group总经理。从2000年6月到2010年11月，Malik先生担任Banc of America Securities，LLC的常务董事。Malik先生在德里大学（Delhi University）获得经济学学士学位，并在波士顿大学管理研究生院（Boston University Graduate School of Management）获得工商管理硕士学位。
- Vikram Malik,serves as Chairman of the board of directors of Alphaeon Credit Inc., a consumer credit provider to the aesthetics industry and as a member of the board of directors of Crown Sterling Limited, LLC, a social media technology company and Ceyeber Inc., an ophthalmic medical device company. From December 2020 to July 2023, Mr. Malik served as President and a director of Priveterra Acquisition Corp. a blank-check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. From April 2014 to July 2023, Mr. Malik served on the board of directors of Aeon Biopharma. From May 2013 to June 2022, Mr. Malik served as the Managing Partner of Strathspey Crown Holdings Group, LLC, a growth equity firm. From August 2011 to May 2013, Mr. Malik served as Vice Chairman, Investment Banking for Deutsche Bank Securities, Inc. From November 2010 to August 2011, Mr. Malik served as a Managing Director in the Healthcare Corporate and Investment Banking Group of Merrill Lynch, Pierce, Fenner & Smith Incorporated. From June 2000 to November 2010, Mr. Malik served as the Managing Director of Banc of America Securities, LLC. Mr. Malik received a B.A. in Economics from Delhi University and an M.B.A. from Boston University Graduate School of Management.
- Albert G. White III
-
Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From August 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a member of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech. - Albert G. White III，他曾担任The Cooper Companies， Inc.的总裁兼首席执行官和成员。自2018年5月起担任董事会成员。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，他还分别从2015年12月和2011年7月担任执行副总裁和首席战略官。从2015年8月到2018年5月，White先生还负责The Cooper Companies， Inc.的女性医疗保健业务，并担任Cooper Medical Inc. （CooperSurgical的母公司）的首席执行官。此前，他从2007年11月到2013年3月担任投资者关系副总裁，从2006年4月到2012年12月担任副总裁兼财务主管。在加入本公司之前，White先生曾担任KeyBank Capital Markets董事三年，并在KeyBank National Association担任多个领导职位。他持有Virginia Tech的金融学士学位和工商管理硕士学位。
- Albert G. White III has served as President & Chief Executive Officer and as a member of Board of Directors since May 2018. Under his leadership, CooperCompanies has developed into a unified, synergistic operating company and global medical device leader – driving strong revenue and profit growth through organizational evolution while elevating CooperVision to the world's #1 contact lens company by arers and CooperSurgical to the global leader in fertility devices and a U.S. leader in highrisk labor and delivery safety. Prior to his appointment as CEO, Mr. White served in vario leadership roles across CooperCompanies, developing an intimate understanding of the biness and its markets. He served as Chief Financial Officer from November 2016 to May 2018 and as EVP and Chief Strategy Officer beginning in 2015 and 2011, respectively. From August 2015 to May 2018, he also led the Company's women's healthcare biness and served as CEO of Cooper Medical Inc., the parent company of CooperSurgical. Earlier in his tenure at CooperCompanies, he held the roles of VP, Investor Relations (2007–2013) and VP and Treasurer (2006–2012). Before joining CooperCompanies, Mr. White spent three years as a Director at KeyBanc Capital Markets and held numero positions of increasing responsibility within KeyBank National Association over the prior eight years. Mr. White also serves as a member of the Board of Directors of Evol, Inc. (NASDAQ: EOLS), a performance beauty company building an aesthetic portfolio of consumer brands. He is Chair of the Compensation Committee and a member of the Audit Committee. Mr. White holds a B.S. in Finance and an MBA, both from Virginia Tech.
- David Gill
-
David Gill，自2018年2月起担任Evolus， Inc.董事会成员。从2021年2月到2021年10月，Gill先生在医疗设备和生命科学行业拥有超过30年的经验，最近担任Perspectum， Ltd的首席财务官，这是一家医疗技术公司，改变了代谢疾病和癌症的临床管理。他目前还担任Y-mAbs Therapeutics， Inc.以及几家私人公司的董事。此前，他于2019年9月至2021年10月担任Strongbridge Biopharma， PLC董事会成员，2015年1月至2019年7月担任Histogenics， Inc.董事会成员，2012年4月至2020年4月担任Melinta Therapeutics， Inc.（f/k/a Cempra Inc.）董事会成员，2018年5月至2020年5月担任Strata Skin Sciences董事会成员。在职业生涯早期，他曾担任多家上市公司的各种高级行政领导职务，包括EndoChoice， Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc.和Novoste Corporation。他持有Wake Forest University的会计学学士学位和Emory University的工商管理硕士学位，是一名注册会计师（非在职）。
David Gill,served as the Chief Financial Officer of Perspectum, Ltd, a healthcare technology company which transforms the clinical management of metabolic disease and cancer. Mr. Gill also currently serves as a director of Y-mAbs Therapeutics, Inc. as well as several private companies. Previously he served on the board of directors of Strongbridge Biopharma, PLC from September 2019 to October 2021, Histogenics, Inc. from January 2015 to July 2019, Melinta Therapeutics, Inc (f/k/a Cempra Inc. from April 2012 to April 2020, and Strata Skin Sciences from May 2018 to May 2020). Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including EndoChoice, Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive). - David Gill，自2018年2月起担任Evolus， Inc.董事会成员。从2021年2月到2021年10月，Gill先生在医疗设备和生命科学行业拥有超过30年的经验，最近担任Perspectum， Ltd的首席财务官，这是一家医疗技术公司，改变了代谢疾病和癌症的临床管理。他目前还担任Y-mAbs Therapeutics， Inc.以及几家私人公司的董事。此前，他于2019年9月至2021年10月担任Strongbridge Biopharma， PLC董事会成员，2015年1月至2019年7月担任Histogenics， Inc.董事会成员，2012年4月至2020年4月担任Melinta Therapeutics， Inc.（f/k/a Cempra Inc.）董事会成员，2018年5月至2020年5月担任Strata Skin Sciences董事会成员。在职业生涯早期，他曾担任多家上市公司的各种高级行政领导职务，包括EndoChoice， Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc.和Novoste Corporation。他持有Wake Forest University的会计学学士学位和Emory University的工商管理硕士学位，是一名注册会计师（非在职）。
- David Gill,served as the Chief Financial Officer of Perspectum, Ltd, a healthcare technology company which transforms the clinical management of metabolic disease and cancer. Mr. Gill also currently serves as a director of Y-mAbs Therapeutics, Inc. as well as several private companies. Previously he served on the board of directors of Strongbridge Biopharma, PLC from September 2019 to October 2021, Histogenics, Inc. from January 2015 to July 2019, Melinta Therapeutics, Inc (f/k/a Cempra Inc. from April 2012 to April 2020, and Strata Skin Sciences from May 2018 to May 2020). Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including EndoChoice, Inc., NxStage Medical, Inc., CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. in Accounting from Wake Forest University and an M.B.A. from Emory University, and is a certified public accountant (inactive).
- David Moatazedi
-
David Moatazedi自2020年9月起担任公司董事。David Moatazedi先生一直担任Evol，Inc.（“Evol”）（纳斯达克股票代码：EOLS）的总裁兼首席执行官、董事会成员，自2018年5月起。Evol是一家上市的生命科学公司，总部位于加利福尼亚州Orange County，市值约为5亿美元。2017年3月至2020年6月，David还担任Obalon Therapeutics的独立董事会成员，Obalon Therapeutics是一家上市的生命科学公司，后来并入了ReShape Lifesciences公司。2016年至2018年，David Moatazedi先生担任Allergan Inc.（“Allergan”）的高级副总裁，以及美国医疗美学部门的负责人。自2005年以来，David Moatazedi先生还在Allergan的多个其他领导职位任职，包括美国面部美学销售和营销副总裁，以及美国整形外科部门。在Allergan之前，从2000年到2005年，David Moatazedi先生是一家跨国制药公司诺华制药的地区经理。David Moatazedi先生拥有佩珀代因大学MBA学位和加州州立大学长滩分校学士学位。
David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach. - David Moatazedi自2020年9月起担任公司董事。David Moatazedi先生一直担任Evol，Inc.（“Evol”）（纳斯达克股票代码：EOLS）的总裁兼首席执行官、董事会成员，自2018年5月起。Evol是一家上市的生命科学公司，总部位于加利福尼亚州Orange County，市值约为5亿美元。2017年3月至2020年6月，David还担任Obalon Therapeutics的独立董事会成员，Obalon Therapeutics是一家上市的生命科学公司，后来并入了ReShape Lifesciences公司。2016年至2018年，David Moatazedi先生担任Allergan Inc.（“Allergan”）的高级副总裁，以及美国医疗美学部门的负责人。自2005年以来，David Moatazedi先生还在Allergan的多个其他领导职位任职，包括美国面部美学销售和营销副总裁，以及美国整形外科部门。在Allergan之前，从2000年到2005年，David Moatazedi先生是一家跨国制药公司诺华制药的地区经理。David Moatazedi先生拥有佩珀代因大学MBA学位和加州州立大学长滩分校学士学位。
- David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach.
- Brady Stewart
-
布雷迪·斯图尔特，自2022年1月起担任Evolus，Inc.董事会成员。斯图尔特夫人自2021年4月起担任Forma Brands，LLC的首席商务官。从2007年5月到2021年4月，斯图尔特女士在Levi Strauss & Co.担任过多个职位，并在美国消费者直销公司担任高级副总裁和董事总经理。斯图尔特女士拥有哈佛商学院战略与运营工商管理硕士学位，并在普林斯顿大学获得比较文学学士学位。
Brady Stewart,has served as the Chief Executive Officer of Bay FC, a professional football club in the National Women's Soccer League. From April 2021 to 2022, Mrs. Stewart served as the Chief Commercial Officer of Forma Brands, LLC, an incubator and accelerator for beauty brands. From May 2007 to April 2021, Mrs. Stewart held multiple roles at Levi Strauss & Co., a global apparel company, culminating in the position of Senior Vice President and Managing Director, U.S. Direct to Consumer. Mrs. Stewart holds an M.B.A in Strategy and Operations from Harvard Business School and received a Bachelor's degree in Comparative Literature from Princeton University. - 布雷迪·斯图尔特，自2022年1月起担任Evolus，Inc.董事会成员。斯图尔特夫人自2021年4月起担任Forma Brands，LLC的首席商务官。从2007年5月到2021年4月，斯图尔特女士在Levi Strauss & Co.担任过多个职位，并在美国消费者直销公司担任高级副总裁和董事总经理。斯图尔特女士拥有哈佛商学院战略与运营工商管理硕士学位，并在普林斯顿大学获得比较文学学士学位。
- Brady Stewart,has served as the Chief Executive Officer of Bay FC, a professional football club in the National Women's Soccer League. From April 2021 to 2022, Mrs. Stewart served as the Chief Commercial Officer of Forma Brands, LLC, an incubator and accelerator for beauty brands. From May 2007 to April 2021, Mrs. Stewart held multiple roles at Levi Strauss & Co., a global apparel company, culminating in the position of Senior Vice President and Managing Director, U.S. Direct to Consumer. Mrs. Stewart holds an M.B.A in Strategy and Operations from Harvard Business School and received a Bachelor's degree in Comparative Literature from Princeton University.
高管简历
中英对照 | 中文 | 英文- Rui Avelar
Rui Avelar，医学博士，自2014年1月起担任我们的首席医疗官，并担任Alphaeon的首席医疗官。从2011年3月到2013年12月，他曾担任Allergan Medical公司的首席医疗官，在那里他负责临床开发、临床操作、安全、医学写作、生物统计和监管事务。Avelar博士拥有多伦多大学（University of Toronto）的医学博士学位，并获得了加拿大运动医学学院（Canadian Academy of Sports Medicine）的运动医学培训认证。
Rui Avelar,served as the Chief Medical Officer of Alphaeon Corporation. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.- Rui Avelar，医学博士，自2014年1月起担任我们的首席医疗官，并担任Alphaeon的首席医疗官。从2011年3月到2013年12月，他曾担任Allergan Medical公司的首席医疗官，在那里他负责临床开发、临床操作、安全、医学写作、生物统计和监管事务。Avelar博士拥有多伦多大学（University of Toronto）的医学博士学位，并获得了加拿大运动医学学院（Canadian Academy of Sports Medicine）的运动医学培训认证。
- Rui Avelar,served as the Chief Medical Officer of Alphaeon Corporation. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.
- Tatjana Mitchell
Tatjana Mitchell，自2023年4月起担任Experian北美财务高级副总裁。2019年5月至2023年3月，Mitchell女士担任Experian North America Consumer Services的首席财务官。2015年12月至2019年5月，Mitchell女士担任Zulily的财务副总裁兼首席财务官，Zulily是一家在线零售商，也是Qurate Retail的子公司。Mitchell女士拥有陶森大学工商管理学士学位和宾夕法尼亚大学沃顿商学院MBA学位。
Tatjana Mitchell,served as the Senior Vice President, Finance of Experian North America since April 2023. From May 2019 to March 2023, Ms. Mitchell served as the Chief Financial Officer for Experian North America Consumer Services. From December 2015 to May 2019, Ms. Mitchell served as the Vice President of Finance and Chief Financial Officer of Zulily, an online retailer and subsidiary of Qurate Retail. Ms. Mitchell holds a B.S. in Business Administration from Towson University and an MBA from the Wharton School at the University of Pennsylvania.- Tatjana Mitchell，自2023年4月起担任Experian北美财务高级副总裁。2019年5月至2023年3月，Mitchell女士担任Experian North America Consumer Services的首席财务官。2015年12月至2019年5月，Mitchell女士担任Zulily的财务副总裁兼首席财务官，Zulily是一家在线零售商，也是Qurate Retail的子公司。Mitchell女士拥有陶森大学工商管理学士学位和宾夕法尼亚大学沃顿商学院MBA学位。
- Tatjana Mitchell,served as the Senior Vice President, Finance of Experian North America since April 2023. From May 2019 to March 2023, Ms. Mitchell served as the Chief Financial Officer for Experian North America Consumer Services. From December 2015 to May 2019, Ms. Mitchell served as the Vice President of Finance and Chief Financial Officer of Zulily, an online retailer and subsidiary of Qurate Retail. Ms. Mitchell holds a B.S. in Business Administration from Towson University and an MBA from the Wharton School at the University of Pennsylvania.
- David Moatazedi
David Moatazedi自2020年9月起担任公司董事。David Moatazedi先生一直担任Evol，Inc.（“Evol”）（纳斯达克股票代码：EOLS）的总裁兼首席执行官、董事会成员，自2018年5月起。Evol是一家上市的生命科学公司，总部位于加利福尼亚州Orange County，市值约为5亿美元。2017年3月至2020年6月，David还担任Obalon Therapeutics的独立董事会成员，Obalon Therapeutics是一家上市的生命科学公司，后来并入了ReShape Lifesciences公司。2016年至2018年，David Moatazedi先生担任Allergan Inc.（“Allergan”）的高级副总裁，以及美国医疗美学部门的负责人。自2005年以来，David Moatazedi先生还在Allergan的多个其他领导职位任职，包括美国面部美学销售和营销副总裁，以及美国整形外科部门。在Allergan之前，从2000年到2005年，David Moatazedi先生是一家跨国制药公司诺华制药的地区经理。David Moatazedi先生拥有佩珀代因大学MBA学位和加州州立大学长滩分校学士学位。
David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach.- David Moatazedi自2020年9月起担任公司董事。David Moatazedi先生一直担任Evol，Inc.（“Evol”）（纳斯达克股票代码：EOLS）的总裁兼首席执行官、董事会成员，自2018年5月起。Evol是一家上市的生命科学公司，总部位于加利福尼亚州Orange County，市值约为5亿美元。2017年3月至2020年6月，David还担任Obalon Therapeutics的独立董事会成员，Obalon Therapeutics是一家上市的生命科学公司，后来并入了ReShape Lifesciences公司。2016年至2018年，David Moatazedi先生担任Allergan Inc.（“Allergan”）的高级副总裁，以及美国医疗美学部门的负责人。自2005年以来，David Moatazedi先生还在Allergan的多个其他领导职位任职，包括美国面部美学销售和营销副总裁，以及美国整形外科部门。在Allergan之前，从2000年到2005年，David Moatazedi先生是一家跨国制药公司诺华制药的地区经理。David Moatazedi先生拥有佩珀代因大学MBA学位和加州州立大学长滩分校学士学位。
- David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach.